PATENT CLAIM ANALYSIS

Application Number: 16362551
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["424", "093210"]

Abstract:
The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1 H ) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

Claim (Index 8):
The engineered immune cell of  claim 1 , wherein the encoded binding protein comprises a TCR \u03b2-chain comprising the amino acid sequence of any one of SEQ ID NOS: 27, 29, 31, 33, 35, 37, 108, 110, 112, 114, 116, and 118.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 99.0
- Lexical Diversity: 1.64474
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14813782', '15006224', '13500123', '14830392', '15301686']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6881499111433095
- 35 USC 102 Novelty (BERT): 0.5378431864881192
- Combined Prediction Score: 0.6731192386777904
- Mean Citation Score: 297.5274
- Max Citation Score: 362.96222
- Similarity Product: 266.51676071256884

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test